Guardant Health acquired MCED startup MetaSight Diagnostics for $59 million upfront plus contingent payments and projected strong growth for its Shield colorectal screening product in 2026. Management guided screening revenue to $162–174 million and expected test volumes to rise to 210,000–225,000, citing commercial traction, physician demand, and partnerships that expand ordering access. Guardant said Shield’s momentum is driven by uptake among unscreened patients and planned integrations with major laboratory partners. The acquisition and guidance signal an intensified commercial push in blood‑based screening, positioning Guardant to scale screening revenues while maintaining its oncology diagnostics franchise.